XOSL
TRMED
Market cap166mUSD
Oct 07, Last price
4.43NOK
1D
0.23%
1Q
2.78%
Jan 2017
-95.41%
IPO
-85.23%
Name
Nordic Nanovector ASA
Chart & performance
P/E
—
P/S
3,987.02
EPS
—
Div yield, %
—
Shrs. gr., 5y
36.34%
Rev. gr., 5y
-11.99%
Revenues
400k
Net income
-58m
L+37.41%
CFO
-42m
L+75.11%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2017, Thor Medical ASA, with its headquarters in Oslo, Norway, specializes in the development and provision of alpha-particle emitters for oncology treatments within Norway.
Related entities
Subsidiaries
TM TECHNOLOGIES AS
Key people
Ludvik Sandnes
Independent Chairman of the Board · since 2023
Jasper Kurth
Chief Executive Officer · since 2024
Brede Ellingsaeter
Chief Financial and Operating Officer · since 2025
Alf Bjornseth
Executive Vice President - Business Development · since 2024
Sindre Hassfjell
Chief Technology Officer · since 2023
Astrid Liland
Vice President - HSEQ · since 2024
Therese Kvehaugen
Executive Vice President - Human Resources · since 2026
Mathias Reierth
Head of Communications and Corporate Affairs · since 2026
John Andersen
Director · since 2023
Mimi Berdal
Independent Director · since 2023
Headquarters & legal address
Kjelsåsveien 168B
Oslo 0884
NO
Oslo 0884
NO
Previous name
Nordic Nanovector ASA
Valuation
Title NOK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||